If you look at the charts for both ENS and JCI for 2013, their run-up commenced well in advance of any reported trouble at Exide. And many of the factors cited by Exide as detriments could easily and equally be seen as similarly impacting their competitors... rising lead costs, strengthening dollar vs. Euro, etc.
If you look at the charts for both ENS and JCI for 2013, their run-up commenced well in advance of any reported trouble at Exide. And many of the factors cited by Exide as detriments could easily and equally be seen as similarly impacting their competitors... rising lead costs, strengthening dollar vs. Euro, etc.